Submicron-sized hydrogels incorporating cyclic dinucleotides for selective delivery and elevated cytokine release in macrophages. (1st January 2016)

• Record Type: Journal Article
• Authors: Lee, Eunjoo; Jang, Hyo-Eun; Kang, Yoon Young; Kim, Jihyun; Ahn, Joong-Hoon; Mok, Hyejung
• Is Part Of: Acta biomaterialia. Volume 29(2015)
• Page Start: 271
• Page End: 281
• Publication Date: 2016-01-01
• Subjects: Cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) -- Hydrogel -- Linear polyethyleneimine (LPEI) -- Cytokine -- Antigen-presenting cells -- Adjuvant; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1016/j.actbio.2015.10.025
• Languages: English
• ISSNs: 1742-7061

Abstract

Graphical abstract: Abstract: Despite the emerging evidences supporting the potential of cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) as a vaccine adjuvant, few properly designed micro-/nanocarriers for the delivery of cyclic dinucleotides have been developed. In this study, we formulated cGAMP within linear polyethyleneimine (LPEI)/hyaluronic acid (HA) hydrogels via inverse water-in-oil (W/O) emulsion/crosslinking. Spherical and cationic LPEI/HA hydrogels (LH gels) with a size of 455.3 ± 3.1 nm and a surface charge of 48.7 ± 3.7 mV were selectively and efficiently delivered into phagocytic macrophage cells, which are one type of antigen-presenting cells (APCs), but not into non-phagocytic fibroblast cells. LH gels incorporating cGAMP (LH/cGAMP gels) elicited excellent induction of the cytokines interferon-β (IFN-β) and interleukin-6 (IL-6). In particular, the amount of IFN-β released by LH hydrogels was significantly increased by 2.5-fold compared to that released by conventional cationic liposomes, such as Lipofectamine. In addition, fabricated LH gels showed superior biocompatibility in phagocytic cell lines and primary bone marrow-derived macrophages (BMDMs). After intramuscular injection with ovalbumin into C57BL/6 mice, LH/cGAMP gels exhibited significantly elevated levels of anti-ovalbumin total IgG in serum and IFN-β mRNA in spleens. Thus, the newly designed cGAMP-incorporating hydrogels can serve as safe and potent adjuvants for vaccination and immunotherapy. Statement of significance: Since cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) was first found as a second messenger of immune signaling in human systems in February 2013 (Science, 15, 826), several scientific studies have been reported related to the potential of cGAMP as a vaccine adjuvant or additive for immunotherapy. However, only naked cGAMP without carriers were studied via intramuscular or intranasal administration so far. In our study, we first investigated the feasibility of polymeric hydrogels incorporating cGAMP in terms of selective uptake into phagocytic antigen presenting cells (APCs), induction of cytokines, production of target antibodies, and biocompatibility for vaccination and immunotherapy in vitro and in vivo . Therefore, we believe this manuscript would be of great interest to the biomaterial communities especially who are studying immunotherapy.